Verdict: KEEP at 1.62% Benchmark Weight

No edge to remove. $265B market cap, 15+ analysts, 2.4% short interest, zero informed bears. Every fundamental metric accelerating into a confirmed multi-year WFE upcycle. Removing LRCX is a 64% factor bet (anti-tech, anti-momentum) at zero IC with every informed semi equipment analyst on the other side.

Factor Decomposition

Regression output (250 trading days, multivariate):

Trailing alpha: +79.8% annualized. Idio vol: 32.1%. R-squared: 63.7%.

Only 36% of LRCX variance is stock-specific. The rest is tech-momentum factor exposure. Removing this name from the basket is the mirror image of removing anti-momentum names (MAR, CMCSA, CSX, SBUX, CTAS) -- a factor bet we have no edge on, just pointed the other direction.

Cross-check via yfinance univariate: Beta (SPX) 1.79, idio vol 36.7%, total vol 53.3%. Univariate idio variance = (36.7/53.3)^2 = 47.4% -- higher because univariate doesn't capture the XLK and MTUM loadings that explain the gap. The multivariate decomposition is the informative one.

The trailing alpha (+79.8%) is enormous but reflects structural WFE share gains compounding through a booming cycle. Management says share grew >1pp YoY and is "ahead of internal roadmap." The question is persistence vs mean-reversion. Evidence favors persistence: "multiyear buildout," "sold out," share gains at every successive node, $7.2B recurring services base.

Financials (Verified Against 10-Q Filed 2026-01-29)

Q2 FY2026 (quarter ending Dec 28, 2025):

Full calendar year 2025:

• Revenue $20.6B (+27% YoY). EPS $4.89 (+49% YoY). Gross margin 49.9% -- highest since 2012 Novellus merger. CSBG $7.2B record, installed base >100K chambers. All per CFO Doug Bettinger prepared remarks.

Revenue mix -- the detail that matters:

Systems revenue declined sequentially. Revenue growth was entirely CSBG-driven. The 10-Q confirms: Systems $3,357,493K, CSBG $1,987,298K.

This matters for Q3. Guide is $5.7B +/- $300M (CFO prepared remarks). Assuming CSBG grows to ≈$2.0B, systems must recover to ≈$3.7B+. That's a $350M sequential increase from a segment that just declined $190M. Feasible per "H2 weighted" WFE, but it's the swing variable for April 22 earnings.

Geography (10-Q):

• China 35% ($1,859M), down from 43% prior quarter. "Affiliate rule" timing per CEO. Guided "flattish YoY" absolute, declining as % naturally.
• Korea +5pp to 20%, Taiwan stable at 20%, SE Asia +3pp to 8%. Non-China business filling the gap.

Buybacks: $1.4B in Q2 at avg $154/share (10-Q). Current price $211. Management bought 37% below current price. Full year $3.9B at avg $104. 85% FCF return policy. Company buybacks dwarf all insider selling by ≈100:1.

What the Market is Pricing

Forward P/E 30.6x implies NTM EPS ≈$6.90. Trailing EPS $4.89. Implied growth: +41%.

Building the EPS bridge (fiscal year ends late June):

• H1 FY2026 actual: $2.41 ($1.14 + $1.27)
• Q3 FY2026 consensus: $1.35 (at guide midpoint)
• Q4 FY2026 implied: ≈$1.50-1.60 (H2 weighted ramp)
• FY2026 total: ≈$6.21-6.36
• NTM at $6.90 means market is pricing FY2027 continuation at $7.50+ run-rate

For $211 to be fair at 30.6x forward, the market needs ALL of these:

1. WFE stays $135B+ in 2026, grows into 2027
2. Share gains continue from mid-30s% toward high-30s%
3. CSBG grows HSD/LDD off $7.2B base
4. Gross margins hold 48-50%
5. No material China revenue loss from new export controls

If ANY breaks -- particularly WFE or share gains -- forward P/E re-rates down AND NTM EPS comes down. Double compression.

Options market (April 24 expiration, bracketing Apr 22 earnings):

• Implied earnings move: +/-8.4% ($17.80) extracted from term structure
• IV rank: 81st percentile (elevated but explained by Apr 2 tariffs + Apr 22 earnings)
• IV vs 30-day realized: 74% vs 62% (20% premium -- event risk, not fear)
• Put skew: +18.6% OTM vs ATM (acknowledges cycle-peak tail but nobody buying aggressively)
• P/C ratio: 0.73-0.82 (bullish)
• Unusual: ATM call IV 2.4-3.7% above put IV (atypical -- active near-the-money call buying, possibly institutional earnings upside bets)
• $220 calls for Apr 24: 237 vol on 67 OI (3.5x unusual) -- specific bet on earnings pop

Positioning:

• Short interest: 2.4%, days to cover 2.9. Nobody's against this.
• Max pain: $200 (Apr 17), $220 (Apr 24). Stock at $211 sits between.
• No unusual put accumulation. No informed bearish flow.

Sentiment:

• Reddit: Zero bear chatter. Zero insider/employee cycle-peak signals. No ground truth from fab operators.
• X/Twitter: Zero bears. Semi analysts posting "sold out through 2027." One generic China mention, no specifics.
• The absence of contrarian voices on a stock this large is itself a data point: consensus is fully formed.

Peer Comparison

The one-month drawdown (-15.2%) matches AMAT (-14.6%) and ASML (-14.7%) exactly. KLAC outperformed on lower beta and more defensive positioning (process control vs cyclical deposition/etch). The drawdown rank matches the beta rank. Zero idiosyncratic signal in the selloff -- pure tech/momentum factor driven by April 2 tariff fear.

LRCX has the highest trailing momentum (+185% 1Y) and highest beta (1.79) in the group. It drops most in selloffs and bounces most in recoveries. This is mechanical, not informational.

Bear Case (Steelmanned)

1. Systems revenue stalling. Q2 systems -5.4% sequentially ($3.55B to $3.36B). Growth was CSBG-driven, not equipment. Q3 needs $3.7B+ recovery. If systems flat-lines again, the "accelerating growth" narrative weakens to "CSBG carrying while core equipment demand plateaus."

Counter: Management guided $5.7B total, "H2 weighted" WFE supports systems recovery. But this IS the swing variable for April 22.

2. Cycle peak in window. If WFE peaks before July 10, LRCX drops hardest of any semi equipment name (highest beta). Equipment companies are the most cyclical part of the semiconductor stack.

Counter: CEO says "sold out" through 2027 with cleanroom constraints. CFO says 2027 "also a pretty good year." New fab announcements for 2027-2028 capacity. Peak requires demand destruction from severe tariffs or recession. Possible but no evidence supports it and zero informed voices are calling it.

3. China export escalation. 35% of revenue from China. New BIS restrictions could impair. Already saw "affiliate rule" drop from 43% to 35% in one quarter.

Counter: Market knows this (consensus risk, not edge). Guided "flattish" absolute. Korea, Taiwan, SE Asia filling the gap. $265B company with 15+ analysts -- no informational advantage here.

4. Momentum reversal. Beta-MTUM = 0.76, 24.6% of variance. Vulnerable if momentum as a factor reverses.

Counter: Systematic risk affecting all high-momentum names equally. Not a reason to remove LRCX specifically -- and we already have 5 anti-momentum removes that benefit from reversal. Removing LRCX doubles the anti-momentum bet at zero IC.

5. Tariff shock (April 2). Semi equipment with 35% China exposure. Trade war escalation could compress margins and restrict shipments.

Counter: Already a margin headwind per 10-Q ("reduced factory efficiencies from higher tariff-related spend"). Margins still at cycle highs (49.7%) despite. Systematic risk affecting all semi equipment equally. Not LRCX-specific.

6. Valuation. P/E 43x trailing, 30.6x forward. Above historical semi equipment multiples.

Counter: Revenue +27%, EPS +49%, WFE share gaining. PEG ≈0.6. For a share-gaining equipment company in a "sold out" cycle with $7.2B recurring services, this isn't obviously expensive. Expensive is when growth decelerates and multiple stays -- growth is accelerating.

Counterparty Analysis

If we remove LRCX (short it vs QQQ), we're betting it underperforms the index over 15 weeks. Who's on the other side?

• 15+ sell-side analysts with full cycle models
• Every semiconductor buy-side PM with the same WFE data
• TSMC, Samsung, Intel publicly confirming "sold out" conditions
• ASML, KLAC, AMAT telling the same cycle story
• Company buying back $1.4B/quarter at prices 37% below current

The counterparty is every informed participant in the semi equipment market. They all see the same data. There is no informational edge to exploit.

Compare to our actual removes where we identified specific counterparty errors: VRTX (pharma in tech index, counterparty = index-constrained holders), MELI (management won't optimize margins, counterparty = growth-narrative retail), WBD (merger arb with no catalyst, counterparty = long-dated arb desks).

LRCX has no identifiable counterparty error. Edge = 0.

Corporate Events

COO Patrick Lord retiring effective Mar 6, 2026 (8-K, Feb 3). 20+ year veteran including Novellus era. Replaced by Sesha Varadarajan as EVP/COO. Lord adopted 10b5-1 selling plan Oct 29, 2025: up to ≈177K shares total (direct sales + option exercises + RSU vesting), minimum price conditions, terminates Oct 30, 2026. Standard retirement liquidation.

Anirudh Devgan (Cadence CEO) appointed to Board (8-K, Feb 3). Innovation and Technology Committee. EDA software CEO on semi equipment board -- cross-pollination signal for computational design and manufacturing convergence.

Other insider activity: Board member Mayer: 615 shares (trivial). SVP Fernandes: 25,829 shares with minimum price conditions. Company buybacks ($1.4B/quarter) dwarf all insider selling by ≈100:1.

No red flags. No surprise departures. No activist pressure. Normal corporate governance.

Monitoring Triggers

April 22 earnings (Q3 FY2026). Guide: $5.7B rev +/- $300M, $1.35 EPS +/- $0.10, 49% GM +/- 1%.

Watch specifically:

1. Systems revenue recovery -- must hit ≈$3.7B+ (from $3.36B). If CSBG again carries the headline, growth quality narrative cracks.
2. WFE 2026 guidance -- any revision below $135B signals cycle peaking earlier than expected. This is the single most actionable data point.
3. Gross margin vs 49% -- tariff costs + customer mix headwinds. Below 48% = cost pressures worse than disclosed.
4. China revenue trend -- further decline from 35% = export controls biting harder than guided.
5. 2027 commentary -- any softening from "also a pretty good year" = forward estimates at risk.

April 2 tariff announcements. Near-term vol catalyst for all semi equipment. Systematic risk, not LRCX-specific. Monitor but don't act preemptively.

If miss + guide-down on April 22: reconsider for removal. WFE downward revision specifically would be the catalyst that breaks the thesis -- it would mean the cycle is peaking and the $6.90 NTM EPS embedded in the stock is wrong.

Net Assessment

Worldview holds 10 evidence items on LRCX, all bullish, cumulative LR ≈24,800. Zero bearish evidence. Zero contrarian voices in options, social, or analyst community. The -15.2% one-month drawdown is fully explained by factor exposures (beta 1.79 in a tech selloff) -- no idiosyncratic signal.

This is one of the cleanest KEEPs in the basket. The burden of proof is on removal, and removal cannot meet that burden against a unanimous, informed consensus with no identifiable counterparty error.